Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas transaction involving its long-acting peptide drug metabolism AI discovery platform, which includes a USD 1.2 billion upfront payment, up to USD 3.5 billion in development milestones, and up to USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is the largest among domestic pharmaceutical companies in the year and is comparable to the 2015 upfront payment scale between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a high apparent year-on-year growth in net profit for 2026 [1][3]. Summary by Sections Transaction Details - The deal with AstraZeneca includes a USD 1.2 billion upfront payment, a maximum of USD 3.5 billion in development milestones, and a maximum of USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R (monthly formulations) and three preclinical weight loss pipelines with different mechanisms of action [2]. Platform Mechanism - The company possesses a globally leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company’s pipeline includes significant projects such as EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The company is focusing on filling gaps in its wild-type lung squamous carcinoma layout with PD-1/IL-15 and has ADC pipelines targeting HER3, B7H3, DLL3, among others [3]. Profit Forecast and Valuation - The company’s net profit is projected to be RMB 4.45 billion in 2025 and RMB 8.46 billion in 2026, with corresponding EPS of RMB 0.39 and RMB 0.73 [4][9]. - The target price is set at HKD 19.25, reflecting a 24x PE for 2026, with adjustments made based on the anticipated impact of product procurement [4][11].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas deal for its long-acting peptide drug metabolism AI discovery platform, involving an upfront payment of USD 1.2 billion, potential R&D milestone payments of up to USD 3.5 billion, and sales milestone payments of up to USD 13.8 billion, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is noted as the largest deal in the domestic pharmaceutical sector for the year, comparable to a previous major deal between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a projected rapid year-on-year growth in net profit for 2026 [1]. - The long-acting metabolism platform is considered rare globally, with only Camurus having a similar platform, which enhances the company's competitive position in the overseas weight loss market [2]. Summary by Sections Transaction Details - The deal with AstraZeneca includes an upfront payment of USD 1.2 billion, potential R&D milestones of up to USD 3.5 billion, and sales milestones of up to USD 13.8 billion, along with a royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R and three preclinical weight loss pipelines, with plans for collaboration on four additional projects [2]. Platform Mechanism - The company possesses a leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company has a robust pipeline including EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The ADC pipeline targets HER3, B7H3, DLL3, and aims to address gaps in lung squamous carcinoma treatment [3]. Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are estimated at RMB 4.45 billion, RMB 8.46 billion, and RMB 5.60 billion respectively, with corresponding EPS of RMB 0.39, RMB 0.73, and RMB 0.49 [4][9]. - The company is assigned a PE ratio of 24 times for 2026, with a target price adjustment reflecting market conditions [4][11].